(NASDAQ: GLYC) Glycomimetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Glycomimetics's earnings in 2025 is -$29,486,227.On average, 2 Wall Street analysts forecast GLYC's earnings for 2025 to be -$3,226,605, with the lowest GLYC earnings forecast at -$5,162,567, and the highest GLYC earnings forecast at -$1,290,642. On average, 2 Wall Street analysts forecast GLYC's earnings for 2026 to be -$3,549,265, with the lowest GLYC earnings forecast at -$5,162,567, and the highest GLYC earnings forecast at -$1,935,963.
In 2027, GLYC is forecast to generate -$4,517,246 in earnings, with the lowest earnings forecast at -$4,517,246 and the highest earnings forecast at -$4,517,246.